Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-10

Collegium Pharmaceutical (COLL)

CEO Vikram Karnani was paid $1,715,846 in fiscal year 2025, ↓ down 84.1% from fiscal year 2024, the 1st percentile of its disclosed peer group (SEC filing 0001628280-26-024063 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,870,092
David Dieter total, FY2025
Executive Vice President and General Counsel — highest-paid officer; CEO Vikram Karnani: $1,715,846
1st
CEO (Vikram Karnani) pay percentile vs peers
8:1
CEO-to-median pay ratio
95.98%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Vikram Karnani (President and Chief Executive Officer), FY2025 total compensation $1,715,846 (base salary $875,000) [exec_comp, SEC accession 0001628280-26-024063, filed 2026-04-07]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

COLL's next annual pay disclosure, estimated April 17, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
David Dieter$384,615$0$3,189,732$0$277,183$0$18,562$3,870,092
Executive Vice President and General Counsel
Colleen Tupper559,34002,484,4860449,289021,9403,515,055
Executive Vice President and Chief Financial Officer
Scott Dreyer523,23602,160,4730335,563021,9403,041,212
Executive Vice President and Chief Commercial Officer
Shirley Kuhlmann115,52201,966,013000702,0482,783,583
Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
Thomas Smith492,95901,620,3140315,195017,5402,446,008
Executive Vice President and Chief Medical Officer
Vikram Karnani875,000000835,40605,4401,715,846
President and Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
David Dieter$3,870,092———
Colleen Tupper3,515,0553,189,9722,734,857↑ +325,083
Scott Dreyer3,041,2122,791,3752,612,380↑ +249,837
Shirley Kuhlmann2,783,5833,301,2962,874,147↓ −517,713
Thomas Smith2,446,0082,500,0832,044,802↓ −54,075
Vikram Karnani1,715,84610,780,125—↓ −9,064,279

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Collegium Pharmaceutical's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper COLL reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against COLL
19 companies name COLL as a compensation peer

Each company listed discloses COLL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named COLL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Carlos PayaIndependent Director$609,137
Garen BohlinIndependent Director$366,639
Gino SantiniChair of the Board$400,963
Gwen MelincoffFormer director (through FY2025)$20,549
John FallonIndependent Director$366,268
John FreundIndependent Director$367,268
Michael DonovanIndependent Director—
Michael HeffernanFormer director (through FY2025)$188,205
Nancy LurkerIndependent Director$743,776
Rita Balice-GordonIndependent Director$342,268
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Garen BohlinDirector2026-05-11D8,700$37$323,491CommonForm 4 ↗
Garen BohlinDirector2026-05-11A8,70016143,463CommonForm 4 ↗
Garen BohlinDirector2026-05-11D8,70000Derivative, Class A CommonForm 4 ↗
Nancy LurkerDirector2026-05-13D4,50036161,861CommonForm 4 ↗
Gino SantiniDirector2026-05-14A8,74100CommonForm 4 ↗
Carlos PayaDirector2026-05-14A8,74100CommonForm 4 ↗
Rita Balice-GordonDirector2026-05-14A8,74100CommonForm 4 ↗
Donovan Michael GlancyDirector2026-05-14A17,48200CommonForm 4 ↗
Nancy LurkerDirector2026-05-14A8,74100CommonForm 4 ↗
John FreundDirector2026-05-14A8,74100CommonForm 4 ↗
Garen BohlinDirector2026-05-14A8,74100CommonForm 4 ↗
John FreundDirector2026-05-15D8,70000Derivative, Class A CommonForm 4 ↗
John FreundDirector2026-05-15A8,70016143,463CommonForm 4 ↗
John FreundDirector2026-05-15D4,12735142,547CommonForm 4 ↗
John FreundDirector2026-05-18D2034681CommonForm 4 ↗
Gino SantiniDirector2026-06-08A8,70016143,463CommonForm 4 ↗
Gino SantiniDirector2026-06-08D8,70000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Scott DreyerPSU2025-02-101,9293,858—7,716$150,308
Colleen TupperPSU2025-02-102,2194,437—8,874170,869
Shirley KuhlmannPSU2025-02-101,7563,511—7,022136,789
David DieterPSU2025-03-172,9345,867—11,734220,893
Colleen TupperPSU2025-02-104,4388,875—17,750389,435
Thomas SmithPSU2025-02-102,8945,787—11,574253,934
Shirley KuhlmannPSU2025-02-103,5127,023—14,046308,169
Thomas SmithPSU2025-02-101,4472,894—5,788112,750
David DieterPSU2025-03-172,9345,867—11,734220,541
Thomas SmithPSU2025-02-101,4472,894—5,788111,448
Colleen TupperPSU2025-02-102,2194,437—8,874171,357
Colleen TupperPSU2025-02-102,2194,437—8,874172,866
Thomas SmithPSU2025-02-101,4472,894—5,788111,766
Shirley KuhlmannPSU2025-02-101,7563,511—7,022135,209
David DieterPSU2025-03-172,9345,867—11,734218,956
Shirley KuhlmannRSU2025-02-10——40,965—1,250,252
Thomas SmithRSU2025-02-10——33,762—1,030,416
Colleen TupperRSU2025-02-10——51,768—1,579,959
Scott DreyerRSU2025-02-10——45,016—1,373,888
Scott DreyerPSU2025-02-101,9293,858—7,716148,996
Scott DreyerPSU2025-02-101,9293,858—7,716148,572
Scott DreyerPSU2025-02-103,8607,719—15,438338,710
David DieterRSU2025-03-17——68,449—2,030,882
Shirley KuhlmannPSU2025-02-101,7563,511—7,022135,595
David DieterPSU2025-03-175,86711,734—23,468498,460
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Scott Dreyer$1,373,888$786,586$036.4%
Colleen Tupper1,579,959904,527036.4%
Shirley Kuhlmann1,250,252715,762036.4%
David Dieter2,030,8821,158,850036.3%
Thomas Smith1,030,416589,898036.4%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
David DieterPSU46,936—$2,173,137
Thomas SmithRSU24,934—1,154,444
Scott DreyerRSU28,334—1,311,864
Scott DreyerRSU41,918—1,940,803
Thomas SmithRSU29,525—1,367,008
David DieterRSU77,454—3,586,120
Colleen TupperPSU20,880—966,744
Scott DreyerRSU13,125—607,688
Vikram KarnaniRSU112,010—5,186,063
Colleen TupperRSU42,647—1,974,556
Vikram KarnaniOption97,75831.41—
Vikram KarnaniPSU169,556—7,850,443
Colleen TupperRSU58,578—2,715,161
Colleen TupperPSU35,498—1,643,557
Colleen TupperRSU32,867—1,521,742
Colleen TupperRSU13,125—607,688
Scott DreyerRSU50,938—2,358,429
Thomas SmithRSU38,204—1,768,845
Scott DreyerPSU30,870—1,429,281
Thomas SmithPSU23,150—1,071,845
Scott DreyerPSU18,000—833,400
Thomas SmithPSU15,840—733,392
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation programs are designed to reward the achievement of our short- and long-term strategic objectives and to drive the creation of long-term shareholder value by successfully executing our business strategy.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1426,313,7921,100,7235,64695.98%Passed
20252025-05-1522,867,4142,233,5412,544,26691.1%Passed
20242024-05-1628,311,783350,75536,15098.78%Passed
20232023-05-1827,953,926315,38390,50298.88%Passed
20222022-05-2328,337,587643,45935,82297.78%Passed
20212021-05-2029,689,528353,66046,17098.82%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1495.98%a
20252025-05-1591.1%b
20242024-05-1698.78%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of Executive Vice President, General Counsel and Corporate Secretary • Mr.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of eral Counsel since March 2025.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of erations;”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)8 : 1
CEO total compensation$1,715,846
Median employee compensation$221,391
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Nancy LurkerIndependent · Compliance (Chair) · Compensation$62,893$680,883$0$0$0$743,776
Carlos PayaIndependent · Transaction (Chair) · Nominating and Corporate Governance34,601574,536000609,137
Gino SantiniIndependent · Board Chair · Compensation · Transaction113,695287,268000400,963
John FreundIndependent · Compensation (Chair) · Audit80,000287,268000367,268
Garen BohlinIndependent · Audit (Chair) · Compliance79,371287,268000366,639
John FallonIndependent · Nominating and Corporate Governance (Chair) · Audit · Compliance · Not standing for re-election79,000287,268000366,268
Rita Balice-GordonIndependent · Nominating and Corporate Governance · Transaction55,000287,268000342,268
Michael HeffernanIndependent · Departed during FY41,099147,106000188,205
Gwen MelincoffIndependent · Departed during FY20,549—00020,549
Michael DonovanIndependent · Audit · Compliance · Newly elected000000
Vikram KarnaniEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$275,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 20,000 / 10,000
Stock ownership guideline3x annual cash retainer for non-employee directors
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$566,208
Equity awards (grant-date value)$2,838,865
All other compensation$0
Total cost of the board$3,405,073

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Collegium Pharmaceutical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Collegium Pharmaceutical.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1BioCryst Pharmaceuticals, Inc.2025Jon Stonehouse$728,466$0$11,132,458$1,052,633$12,951,082
2ANI Pharmaceuticals, Inc.2025Nikhil Lalwani837,4097,848,71101,572,50010,278,620
3Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
4Amphastar Pharmaceuticals, Inc.2025Jack Yongfeng Zhang950,9113,301,9813,302,024361,0008,309,350
5ACADIA Pharmaceuticals, Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
6Catalyst Pharmaceuticals, Inc.2024Richard Daly750,0001,267,6015,070,83007,774,160
7Collegium Pharmaceutical2025Vikram Karnani875,00000835,4061,715,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Collegium Pharmaceutical127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
ACADIA Pharmaceuticals, Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Amphastar Pharmaceuticals, Inc.not disclosedOptions 50 · RSU 50not disclosedWillis Towers Watson (WTW)
ANI Pharmaceuticals, Inc.185%RSU 75 · PSU 25Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences IndexPearl Meyer & Partners, LLC
BioCryst Pharmaceuticals, Inc.not disclosednot disclosednot disclosedAon
Catalyst Pharmaceuticals, Inc.not disclosednot disclosednot disclosedMercer LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Collegium Pharmaceutical in fiscal 2025?
As disclosed, David Dieter (Executive Vice President and General Counsel) was the highest-paid executive at Collegium Pharmaceutical in fiscal 2025, with total compensation of $3,870,092.
How does Collegium Pharmaceutical's chief executive pay compare to its disclosed peer group?
As disclosed, Vikram Karnani's total compensation ranked at the 1st percentile of Collegium Pharmaceutical's disclosed peer group.
What is Collegium Pharmaceutical's CEO-to-median employee pay ratio?
As disclosed, Collegium Pharmaceutical's CEO-to-median employee pay ratio was 8:1.
How did shareholders vote on Collegium Pharmaceutical's executive compensation?
As disclosed, 95.98% of shareholders supported Collegium Pharmaceutical's executive compensation in the latest say-on-pay vote.
How much does Collegium Pharmaceutical spend in total on board compensation for fiscal 2025?
As disclosed, Collegium Pharmaceutical reported total board compensation of $3,405,073 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, David DieterDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 3,870,092. Filing ↗machine: r8 · c48 · span 801432–801441
2Section 01, Colleen TupperDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 3,515,055. Filing ↗machine: r5 · c48 · span 790338–790347
3Section 01, Scott DreyerDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 3,041,212. Filing ↗machine: r11 · c48 · span 812129–812138
4Section 01, Shirley KuhlmannDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 2,783,583. Filing ↗machine: r17 · c48 · span 834020–834029
5Section 01, Thomas SmithDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 2,446,008. Filing ↗machine: r14 · c48 · span 823230–823239
6Section 01, Vikram KarnaniDEF 14A2026-04-070001628280-26-024063Section “Summary Compensation Table”. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
7Section 03, Scott Dreyer PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 893172–893179
8Section 03, Colleen Tupper PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 866204–866211
9Section 03, Shirley Kuhlmann PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 922788–922795
10Section 03, David Dieter PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 883384–883391
11Section 03, Colleen Tupper PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 871131–871138
12Section 03, Thomas Smith PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 915279–915286
13Section 03, Shirley Kuhlmann PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 930178–930185
14Section 03, Thomas Smith PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 907889–907896
15Section 03, David Dieter PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 880919–880926
16Section 03, Thomas Smith PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 910352–910359
17Section 03, Colleen Tupper PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 868667–868674
18Section 03, Colleen Tupper PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 863741–863748
19Section 03, Thomas Smith PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 912815–912822
20Section 03, Shirley Kuhlmann PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 925251–925258
21Section 03, David Dieter PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 878454–878461
22Section 03, Shirley Kuhlmann RSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 932312–932321
23Section 03, Thomas Smith RSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 917413–917422
24Section 03, Colleen Tupper RSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 873265–873274
25Section 03, Scott Dreyer RSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 902696–902705
26Section 03, Scott Dreyer PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 898098–898105
27Section 03, Scott Dreyer PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 895635–895642
28Section 03, Scott Dreyer PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 900562–900569
29Section 03, David Dieter RSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 887985–887994
30Section 03, Shirley Kuhlmann PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 927714–927721
31Section 03, David Dieter PSUDEF 14A1900-01-010001628280-26-024063Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 885850–885857
32Section 07, pay ratioDEF 14A2026-04-070001628280-26-024063Section “CEO Pay Ratio”. As printed: 8 : 1. Filing ↗machine: span 1114023–1114024
33Section 08, Nancy LurkerDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 743,776. Filing ↗machine: t50 · r7 · c8 · span 487255–487558
34Section 08, Carlos PayaDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 609,137. Filing ↗machine: t50 · r9 · c8 · span 490574–490877
35Section 08, Gino SantiniDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 400,963. Filing ↗machine: t50 · r10 · c8 · span 492040–492343
36Section 08, John FreundDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 367,268. Filing ↗machine: t50 · r5 · c8 · span 483938–484241
37Section 08, Garen BohlinDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 366,639. Filing ↗machine: t50 · r3 · c8 · span 480998–481301
38Section 08, John FallonDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 366,268. Filing ↗machine: t50 · r4 · c8 · span 482468–482771
39Section 08, Rita Balice-GordonDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 342,268. Filing ↗machine: t50 · r2 · c8 · span 479471–479805
40Section 08, Michael HeffernanDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 188,205. Filing ↗machine: t50 · r6 · c8 · span 485602–485905
41Section 08, Gwen MelincoffDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 20,549. Filing ↗machine: t50 · r8 · c2 · span 488161–488399
42Section 08, Michael DonovanDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 0. Filing ↗
43Section 08, Vikram KarnaniDEF 14A2026-04-070001628280-26-024063Section “Director Compensation”. As printed: 0. Filing ↗
44Section 02, Garen Bohlin 2026-05-11Form 42026-05-130001254705-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Garen Bohlin 2026-05-11Form 42026-05-130001254705-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Garen Bohlin 2026-05-11Form 42026-05-130001254705-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Nancy Lurker 2026-05-13Form 42026-05-150001450485-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Gino Santini 2026-05-14Form 42026-05-180001276038-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Carlos Paya 2026-05-14Form 42026-05-180001606244-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Rita Balice-Gordon 2026-05-14Form 42026-05-180001825625-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Donovan Michael Glancy 2026-05-14Form 42026-05-180002134015-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Nancy Lurker 2026-05-14Form 42026-05-180001450485-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, John Freund 2026-05-14Form 42026-05-180001296771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Garen Bohlin 2026-05-14Form 42026-05-180001254705-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, John Freund 2026-05-15Form 42026-05-180001296771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, John Freund 2026-05-15Form 42026-05-180001296771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, John Freund 2026-05-15Form 42026-05-180001296771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, John Freund 2026-05-18Form 42026-05-200001296771-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Gino Santini 2026-06-08Form 42026-06-100001276038-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Gino Santini 2026-06-08Form 42026-06-100001276038-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
61Section 06, 2026 voteForm 8-K2026-05-150001104659-26-062536Item 5.07 · say-on-pay result. As reported: 95.98% (votes for as printed: 26,313,792). Filing ↗
62Section 06, 2025 voteForm 8-K2025-05-190001104659-25-050435Item 5.07 · say-on-pay result. As reported: 91.1% (votes for as printed: 22,867,414). Filing ↗
63Section 06, 2024 voteForm 8-K2024-05-200001104659-24-063396Item 5.07 · say-on-pay result. As reported: 98.78% (votes for as printed: 28,311,783). Filing ↗
64Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
65Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
66Section 09b board cost (computed)Computed——Cash 566,208 + equity 2,838,865 + all other 0 = 3,405,073, summed across the director compensation table rows.machine: formula: Σ = 3,405,073
67BioCryst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
68ANI Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-090001023024-26-000039CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154
69Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
70Amphastar Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-130001297184-26-000023CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932
71ACADIA Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗
72Catalyst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-110001193125-25-079097CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗
73Collegium Pharmaceutical (subject), Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceutical's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
74Section 10a, ANI Pharmaceuticals, Inc. reciprocityDEF 14A—0001023024-26-000039ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗
75Section 10a, BioCryst Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-026822BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗
76Section 10a, ACADIA Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗
77Section 10a, Catalyst Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-25-079097Catalyst Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗
78Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗
79Section 10a, Amphastar Pharmaceuticals, Inc. reciprocityDEF 14A—0001297184-26-000023Amphastar Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.